The biopharmaceutical company Array BioPharma has formed a collaboration agreement with Biogen Idec  for the discovery and development of inhibitors targeting a kinase for treating autoimmune disorders. 

Under the terms of the agreement, Biogen and Array will collaborate on the discovery of the novel kinase inhibitors. Biogen will be responsible for all aspects of clinical development and commercialization. The agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.

Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat cancer.  It has seven Phase III or pivotal studies in progress or which are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis).

Source: Array BioPharma